Shares of Tylenol maker Kenvue dropped Monday ahead of an anticipated announcement by the Trump administration linking pregnant women’s use of the painkiller to autism. https://t.co/mnfTbfwJiT ...

Tylenol Maker Kenvue Rebounds In Premarket After Trump Links Drug To Autismhttps://t.co/CpUwriH2QR https://t.co/uCtgEYb80p ...

Group 1: Market Overview - U.S. stock index futures showed indecisive movements, with Nasdaq 100 futures up 0.01%, S&P 500 futures down 0.02%, and Dow futures up 0.08% [1] - International gold prices reached new historical highs, with London spot gold hitting $3,791 per ounce and COMEX gold futures peaking at $3,824 per ounce [2] Group 2: Gold Market Dynamics - SPDR Gold Trust reported a 0.6% increase in gold holdings from last Friday to this Monday, reaching 1,000.57 tons, the highest level in over three years [4] - The surge in gold prices is driven by expectations of Federal Reserve interest rate cuts and global demand influenced by inflation and geopolitical risks [2] Group 3: Technology Sector Insights - Nvidia is seen as a key driver of U.S. economic growth, with its AI-driven capital investments helping to prevent a recession despite a slowdown in employment [6] - The market structure is influenced by two main forces: Nvidia's impact on tech sentiment and scrutiny of Federal Reserve policies [6] Group 4: Notable Investments - Cathie Wood's Ark Investment purchased approximately $21 million in Chinese tech stocks, including Alibaba and Baidu, indicating a strategic shift in investment focus [6] Group 5: Other Market News - Kenvue's stock rebounded over 5% after a significant drop due to unfounded claims linking its product Tylenol to autism [7] - DHL announced the resumption of U.S. business parcel services starting September 25, following a temporary suspension due to changes in U.S. tax policy [8]

Core Viewpoint - Kenvue shares experienced a recovery of over 5% in premarket trading after hitting a record low, following comments made by US President Donald Trump regarding the company's popular pain relief product [1] Group 1 - Kenvue's stock price rose more than 5% in premarket trading on Tuesday [1] - The increase in share price comes after the company reached a record low in the previous session [1] - US President Donald Trump's remarks linked to Kenvue's pain relief product contributed to the recovery in stock price [1]

Core Viewpoint - The article discusses the impact of President Trump's warning to pregnant women about the use of Tylenol (acetaminophen), linking it to autism, which led to a significant drop in Kenvue's stock price. However, medical professionals and Kenvue refute this claim, stating there is no scientific evidence supporting such a connection [2][3][7]. Group 1: Stock Market Reaction - Kenvue's stock price fell over 7% to a historical low of $32.57, resulting in a market capitalization of $32.567 billion (approximately 231.6 billion RMB) following Trump's warning [3]. - Following the backlash and lack of scientific support for Trump's claims, Kenvue's stock rebounded by over 5% in pre-market trading [2][3]. Group 2: Medical Community Response - Numerous doctors and Kenvue have stated that there is no scientific evidence linking acetaminophen to autism, emphasizing that such claims could endanger the health of pregnant women [2][7]. - The FDA has indicated that there is no clear evidence that appropriate use of acetaminophen during pregnancy leads to adverse outcomes [5]. Group 3: Research and Studies - A large-scale study published in 2024 analyzing data from nearly 2.5 million siblings in Sweden found no increased risk of autism in children whose mothers used acetaminophen during pregnancy [4]. - The article notes that the diagnosis rate of autism has significantly increased in the U.S., with 1 in 31 children diagnosed, compared to 1 in 150 in 2000, although the reasons for this rise remain unclear [6]. Group 4: Government and Pharmaceutical Company Actions - U.S. health officials are expected to issue warnings against the use of Tylenol during early pregnancy unless necessary, while also promoting a drug called Leucovorin as a potential treatment for autism [8]. - Kenvue has added a section on its website to address media reports, reiterating that there is no evidence linking acetaminophen to autism [7].

Group 1 - The core viewpoint is that independent scientific evidence indicates acetaminophen does not cause autism, as stated by a Kenvue spokesperson [1]

Core Viewpoint - Kenvue's stock experienced volatility following President Trump's comments linking Tylenol to autism, but it rebounded sharply in premarket trading the next day [1][2]. Group 1: Stock Performance - Kenvue's shares fell by 7.5% on Monday but recovered nearly 5% in premarket trading on Tuesday [2][5]. - The stock's recovery indicates investor confidence despite the negative headlines surrounding Tylenol [4]. Group 2: Company Response - Kenvue has disputed any connection between Tylenol and autism, emphasizing the potential risks for pregnant women who might avoid the medication [3]. - The company highlighted that avoiding Tylenol could lead to dangerous alternatives for managing fevers during pregnancy [3]. Group 3: Market Context - The announcement from Trump relied on existing studies rather than new research, which may limit the long-term impact on Tylenol consumption [2][4]. - Analyst Filippo Falorni from Citi Investment Research noted a limited risk of new lawsuits but acknowledged potential negative effects on Tylenol consumption due to the publicity [4].

It's 5AM in New York City. Good morning. I'm Vonnie Quinn with your Bloomberg Brief.Here's what you need to know. World leaders in New York City, the UN general assembly set to kick off in midtown manhattan. President trump is scheduled to speak playing diplomacy.The US ambassador to china says washington and Beijing are in talks for a huge Boeing aircraft order, and US stocks hit another record high of the year. Investors awaiting Fed Chair Powell speech later today and the latest PMI data. And that's wher ...

Kenvue is bracing for an explosion of litigation over its popular pain reliever Tylenol after the Trump administration warned that the drug’s active ingredient is a potential cause of autism https://t.co/5ujxhnMQVh ...

Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn't offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to ... ...